Muscarinic Acetylcholine Receptor M4 - Pipeline Review, H2 2020

Muscarinic Acetylcholine Receptor M4 - Pipeline Review, H2 2020

Summary

According to the recently published report 'Muscarinic Acetylcholine Receptor M4 - Pipeline Review, H2 2020'; Muscarinic Acetylcholine Receptor M4 (CHRM4) pipeline Target constitutes close to 18 molecules.
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Muscarinic acetylcholine receptor M4 or cholinergic receptor muscarinic 4 (CHRM4) is a protein encoded by the CHRM4 gene. It mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins.
The report 'Muscarinic Acetylcholine Receptor M4 - Pipeline Review, H2 2020' outlays comprehensive information on the Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 9 and 2 respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Mouth and Dental Disorders and Ophthalmology which include indications Alzheimer's Disease, Schizophrenia, Psychosis, Parkinson's Disease, Amnesia, Amyotrophic Lateral Sclerosis, Angelman Syndrome, Anxiety Disorders, Cognitive Disorders, Cognitive Impairment, Cognitive Impairment Associated With Schizophrenia (CIAS), Depression, Drug-Induced Dyskinesia, Fragile X Syndrome, Infantile Spasm (West Syndrome), Movement Disorders, Multiple Sclerosis, Neurology, Presbyopia, Rett Syndrome, Sialorrhoea and Tuberous Sclerosis.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M4 (CHRM4)
  • The report reviews Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M4 (CHRM4)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M4 (CHRM4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Overview
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Companies Involved in Therapeutics Development
Anavex Life Sciences Corp
AstraZeneca Plc
Cerevel Therapeutics LLC
Karuna Therapeutics Inc
Lan Sheng Biomedicine Suzhou Co Ltd
NeuroHealing Pharmaceuticals Inc
NeuroSolis Inc
Presbyopia Therapies LLC
Sosei Heptares
Suven Life Sciences Ltd
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Drug Profiles
(aceclidine + tropicamide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(trospium chloride + xanomeline) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
blarcamesine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVL-231 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Agonize CHRM4 for Drug-Induced Dyskinesia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTL-0016878 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LS-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSX-0527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSX-0527f - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSX-0559 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSX-0559f - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize M1 and M4 Muscarinic Acetylcholine Receptors for Psychosis and Cognitive Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Muscarinic Acetylcholine Receptor 4 for Psychosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tropicamide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0467154 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-6000918 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-6001852 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Dormant Products
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Discontinued Products
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Product Development Milestones
Featured News & Press Releases
Sep 10, 2020: Anavex Life Sciences announces completion of ANAVEX2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome clinical trial
Aug 19, 2020: Anavex Life Sciences announces commitment for Financial Investment by Shake It Up Foundation for Parkinson’s Research for clinical trial of ANAVEX®2-73 (Blarcamesine) in patients with Parkinson’s disease
Aug 05, 2020: Anavex Life Sciences receives TGA special access scheme approval for ANAVEX2-73 (blarcamesine) for Alzheimer’s disease patients
Aug 03, 2020: Karuna Therapeutics announces topline data from phase 1b trial evaluating KarXT on experimentally induced pain in healthy volunteers
Jul 02, 2020: Anavex starts dosing patients in Rett syndrome trial
Jul 01, 2020: Anavex Life Sciences announces first patient dosed in EXCELLENCE Phase 2/3 clinical trial of ANAVEX®2-73 (Blarcamesine) in patients with Rett Syndrome
Jun 23, 2020: Karuna Therapeutics announces positive outcome of end-of-phase 2 meeting with the FDA for KarXT for the treatment of acute psychosis in patients with schizophrenia
Jun 16, 2020: Anavex Life Sciences announces exceeding of enrollment target for the ANAVEX 2-73 (blarcamesine) U.S. phase 2 Rett Syndrome clinical trial
Jun 04, 2020: Anavex Life Sciences receives regulatory approval from Health Canada and UK MHRA expanding phase 2b/3 ANAVEX2-73 (blarcamesine) into multinational clinical trial for Alzheimer’s disease
May 27, 2020: Karuna Therapeutics to present additional data from the phase 2 clinical trial of KarXT for the treatment of psychosis in patients with schizophrenia at the American Society of Clinical Psychopharmacology 2020 Annual Meeting
Apr 23, 2020: Anavex Life Sciences announces publication of clinical data for ANAVEX2-73 (blarcamesine) in Alzheimer’s Disease
Feb 24, 2020: Anavex Life Sciences announces publication of foundational data for ANAVEX2-73 (blarcamesine) in multiple sclerosis (MS)
Feb 03, 2020: Anavex Life Sciences announces Fast Track Designation granted by U.S. FDA for ANAVEX2-73 (blarcamesine) clinical development program for the treatment of Rett Syndrome
Jan 27, 2020: Anavex Life Sciences announces achievement of enrollment target for the ANAVEX2-73 (blarcamesine) phase 2 Parkinson’s Disease Dementia (PDD) clinical trial
Jan 08, 2020: Anavex Life Sciences issued new U.S. patent for ANAVEX2-73 treatment of Neurodevelopmental Disorders including Rett Syndrome and Multiple Sclerosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020 (Contd..2), H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Anavex Life Sciences Corp, H2 2020
Pipeline by AstraZeneca Plc, H2 2020
Pipeline by Cerevel Therapeutics LLC, H2 2020
Pipeline by Karuna Therapeutics Inc, H2 2020
Pipeline by Lan Sheng Biomedicine Suzhou Co Ltd, H2 2020
Pipeline by NeuroHealing Pharmaceuticals Inc, H2 2020
Pipeline by NeuroSolis Inc, H2 2020
Pipeline by Presbyopia Therapies LLC, H2 2020
Pipeline by Sosei Heptares, H2 2020
Pipeline by Suven Life Sciences Ltd, H2 2020
Dormant Projects, H2 2020
Discontinued Products, H2 2020
List of Figures
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook